Market News & Trends
Phillips Medisize Expands UK Inhalation Operations With Chippenham Site Acquisition
Phillips Medisize is expanding its UK inhalation operations after acquiring the full Chippenham facility, adding capacity to its Global Inhalation Center of Excellence.
BioLife Advances Oral Peptide Delivery Platform Ahead of London Life Sciences Week
BioLife Products Limited plans to present its oral peptide delivery technology at London Life Sciences Week, as it advances an alternative approach to administering peptide-based medicines.
Biograil Raises Funds to Prepare Oral Drug Delivery Platform for Phase 1 Trials
Biograil has secured $22.4 million in new funding to advance its BIONDD oral drug delivery platform, designed to administer therapeutics typically given by injection, toward Phase 1 trials.
1nhaler Raises $3 Million to Advance Cardboard Inhaler Toward Clinical Trials
1nhaler has raised approximately $3 million in follow-on financing to advance its single-use cardboard dry powder inhaler, targeting its first regulatory approval in 2027.
AbbVie Commits $162 Million to Expand Research and Development Operations in Oxford
AbbVie is investing more than $161.7 million to expand its research and development presence in Oxford, England, adding a new facility focused on drug discovery in immunology, neuroscience and oncology.
AbbVie Licenses Nxera's Experimental IBD Drug in $1.47 Billion Global Deal
AbbVie has secured global rights to Nxera Pharma’s investigational oral IBD drug NXE0033744 in a deal worth up to $1.47 billion, including $100 million upfront.
MadeAi Introduces AI Platform to Streamline Pharmaceutical Dossier Development and Updates
MadeAi has launched Dossier Expert, an AI platform designed to help pharmaceutical and life sciences companies develop and maintain formulary and value dossiers. The platform links content to underlying evidence and can reduce authoring and update timelines by as much as 70%, according to the company.
FDA Issues Final Potency Guidance for Cell and Gene Therapy Manufacturers
The FDA has issued final guidance on potency assurance for cell and gene therapy products, replacing its 2011 guidance and outlining a lifecycle, risk-based strategy for manufacturers. A webinar is set for December 10, 2026.
Novartis Ends Collaboration With BioArctic on BrainTransporter-Based Drug Program
Novartis has terminated its August 2025 collaboration with BioArctic on a BrainTransporter-based therapy; BioArctic retains the $30 million upfront payment and continues developing the platform for CNS drug delivery.
3billion to Present AI-Driven Drug Discovery Platform at BIO-Europe 2026
3billion will present its Genetics-First AI drug discovery platform at BIO-Europe 2026 in Cologne, seeking pharmaceutical and biotech partners for joint research, licensing and commercialization.
Experimental Alzheimer’s Treatment Targets DNA Damage and Brain Inflammation
Scientists at King’s College London report KCL-286, an experimental oral drug, repaired DNA damage and reduced inflammation in a mouse model of Alzheimer’s and has already cleared Phase 1 human safety trials.
Karyopharm Files for Chapter 11 Restructuring, Reaches Merger Agreement With Ayrmid
Karyopharm Therapeutics has filed for Chapter 11 restructuring and reached a merger agreement with Ayrmid Ltd. The company secured up to $55 million in debtor-in-possession financing and targets completion in the first quarter of 2027.
Autoinjectors Market Forecast to Reach $5.52B this Year
The global autoinjectors market is projected to reach $5.52 billion by the end of this year. Rising chronic disease, biologic therapies and home healthcare are driving demand for patient-friendly self-injection devices.
Lonza to Acquire Five U.S. CDMO Sites From Merck KGaA, Broadening Manufacturing Network
Lonza has agreed to acquire five U.S. manufacturing sites from Merck KGaA, expanding its CDMO network to nine U.S. locations. The deal adds about 1,100 employees and new capabilities in bioconjugates, viral vectors and aseptic fill-finish.
FDA Revises Draft Guidance on Drug Delivery Device Performance Requirements
The FDA has released revised draft guidance on essential drug delivery performance characteristics for devices and combination products. The guidance replaces the July 2024 draft and aims to bring consistency and predictability to development and regulatory review.
Neuralink's Blindsight Vision Implant Faces Questions Over Clinical Readiness and Human Trials
Neuralink says its Blindsight brain implant could restore vision and is technically ready pending regulatory approval, but no vision-restoration study is registered and no human evidence has been released. The device’s FDA Breakthrough Device Designation is not an approval.
Fresenius Partners With WuXi Biologics to Add Up to 37 Biosimilar Candidates to Pipeline
Fresenius has signed an exclusive development agreement with WuXi Biologics that could add up to 37 biosimilar candidates to its pipeline, growing its portfolio from 29 to as many as 66 molecules.
Buccal Drug Delivery Market Set to Reach $6.48B by 2030
The global buccal drug delivery market is projected to grow from $3.89 billion in 2025 to $6.48 billion by 2030, as developers pursue faster, non-invasive alternatives to oral and injectable administration.
Yuyu Pharma Eyes Animal Health Market to Broaden Drug Development Opportunities
Yuyu Pharma is exploring opportunities in veterinary medicine as a way to expand its pharmaceutical business and identify new avenues for drug development in human healthcare.
BioMarin Licenses Investigational Fabry Disease Therapy From GC Biopharma and Hanmi Pharm
BioMarin Pharmaceutical has secured exclusive worldwide rights, excluding South Korea, to an investigational enzyme replacement therapy for Fabry disease from GC Biopharma and Hanmi Pharm.
